- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 25.09. | Eli Lilly withdraws phase 2b trial of $1.9B obesity bet before starting enrollment | ||
| 25.09. | Heidelberg to lay off 75% of staff after milestone becomes millstone | ||
| 24.09. | Average biopharma biobucks decline, while upfront deal payments rise: SRS Acquiom | ||
| 24.09. | Sparrow flies forward with $95M series B for midstage diabetes asset | ||
| 24.09. | Harmony's pivotal Fragile X trial flops as high placebo response creates discord | ||
| 24.09. | uniQure hopes to launch 1st Huntington's gene therapy next year following phase 1/2 success | ||
| 24.09. | Cyclerion cycles through latest pivot, reinventing itself as neuro biotech | ||
| 23.09. | Big Pharma-backed Rome Therapeutics nears end of road with planned layoffs and strategic review | ||
| 23.09. | Wall Street spotlight: NYSE honors this year's Fierce 15 winners | ||
| 23.09. | Seres shrinks head count by 25% to fund phase 2 study of infection biotherapeutic | ||
| 23.09. | Bristol Myers midtrial endpoint addition secures phase 3 win in multiple myeloma | ||
| 23.09. | Roche's 'top three' obesity ambition not reliant on developing one megablockbuster | ||
| 23.09. | Merck inks $349M biobucks deal to apply AI to challenging targets | ||
| 22.09. | Big Pharma-backed MapLight plots IPO to advance neuro pipeline | ||
| 22.09. | Italy's Angelini inks $550M-plus pact for preclinical brain condition asset | ||
| 22.09. | Ionis plots FDA filing after rare neurological disease candidate posts phase 3 win | ||
| 22.09. | 'We have the will': Roche unveils strategy to become 'top 3' obesity company | ||
| 22.09. | Sanofi's troubled MS hopeful tolebrutinib hit by FDA delay | ||
| 22.09. | Pfizer inks $4.9B upfront Metsera buyout to beef up obesity pipeline following internal setbacks | ||
| 22.09. | Roche reports phase 3 breast cancer victory, starting key period for oral SERD with a win | ||
| 22.09. | Genfit ends liver failure program after seeing adverse event in phase 2 trial | ||
| 19.09. | Two years after Carmot buyout, what's next for Roche's expensive obesity pipeline? | ||
| 18.09. | Moderna co-founder Robert Langer's son launches new VC with $77.5M, backing from dad | ||
| 18.09. | Carisma Therapeutics' lifeline dissipates as reverse merger plans fall through, Moderna cuts ties | ||
| 18.09. | Biogen strikes $85M Alcyone buyout, securing tech for spinal drug delivery |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .